FindMyKOL

Michael Maricic, MD

Basic profile

University of Arizona

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionTucson, AZ · WestSpecialtyRheumatologyFocusRheumatology/Immunology
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Michael Maricic is a Rheumatology/Immunology physician affiliated with University of Arizona. OpenAlex indexes 69 publications with 3,497 citations (h-index 23).

Overview

Scholarship

indexed output and impact (OpenAlex)
69publications

Publications indexed by OpenAlex. Counts exclude supporting files.

3,497citations

Citations across these publications.

23h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
14companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Radius Health, Inc.
    Program year20253 payments
    $65
  • Organon LLC
    Program year20251 payment
    $22
  • Amgen Inc.
    Program year20243 payments
    $262
All 25 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    64.2%
    TNF inhibitor31.2%
    Certolizumab pegol75%Golimumab14%Infliximab11%Humira(Cf) Pen0%Humira Pen0%Enbrel Sureclick0%Humira(Cf)0%Enbrel0%Cimzia0%Enbrel Mini0%
    Part D + Part B<11 patients
    Interleukin-6 Receptor Antagonist20%
    Tocilizumab100%
    Part B, office-administered≥19 patients

    + 9 more classes in this area

  • Musculoskeletal

    33.5%
    RANK Ligand Inhibitor33.2%
    Denosumab100%
    Part B, office-administered≥482 patients
    Bisphosphonate0.2%
    Zoledronic acid100%
    Part B, office-administered≥39 patients

    + 3 more classes in this area

  • Nervous system

    0.8%
    Nonsteroidal Anti-inflammatory Drug0.3%
    Meloxicam75%Diflunisal19%Ibuprofen6%
    Part D<11 patients
    Opioid Agonist0.3%
    Tramadol Hcl71%Oxycodone-Acetaminophen29%
    Part D≥36 patients

    + 5 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”